Trust Signals
Key Takeaways
- SLU-PP-332 is a pan-ERR (estrogen-related receptor alpha, beta, gamma) agonist with a molecular weight of 397.47 g/mol. It is not a peptide, it is a small molecule.
- The only published in-vivo efficacy data come from one mouse study (Bhatt et al., 2023, Nature Communications) using 30 mg/kg/day subcutaneously. No human trials exist.
- SLU-PP-332 requires a DMSO plus cyclodextrin vehicle for injection. Bacteriostatic water alone will not dissolve it at useful concentrations.
- COA minimum for injectable-grade material: HPLC purity above 98%, mass-spec confirmed molecular weight, endotoxin below 1 EU/mg.
- The "exercise mimetic" label comes from a gene-expression overlap with endurance training in rodents. It does not mean the compound replicates exercise outcomes in humans.
What Is SLU-PP-332 Injectable and Should Researchers Use It?
SLU-PP-332 injectable is a subcutaneous research administration route for a small-molecule pan-ERR agonist developed at St. Louis University. It is the preferred route in published rodent work because oral bioavailability is low and variable. No human safety or efficacy data exist. Researchers should treat it as a mechanistic probe, not a validated intervention.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is SLU-PP-332?
- Evidence ledger: what the data actually shows
- How does SLU-PP-332 work at the receptor level?
- How do you reconstitute SLU-PP-332 for injection?
- What dose has been used in research?
- What most pages get wrong about SLU-PP-332 injectable
- Stability and storage: the chemistry behind the rules
- How to read a COA for injectable-grade SLU-PP-332
- Honest head-to-head: SLU-PP-332 vs. comparable research compounds
- What are the real risks?
- FAQ
- Sources
- Footer disclaimers
What Exactly Is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule, not a peptide, despite being marketed alongside peptides. Its full chemical name is (4-(((2S)-2-(((1R)-1-(naphthalen-1-yl)ethyl)amino)propanoyl)amino)benzoyl)glycine, and its molecular weight is 397.47 g/mol. It was synthesized and characterized at St. Louis University and reported in peer-reviewed literature beginning around 2022 to 2023. Its mechanism is agonism at all three estrogen-related receptors: ERR alpha, ERR beta, and ERR gamma. These orphan nuclear receptors regulate genes involved in mitochondrial biogenesis, fatty-acid oxidation, and oxidative phosphorylation.
The "injectable" designation in research refers to subcutaneous administration in animal models. The compound must be specially formulated because it is lipophilic and poorly water-soluble.
Evidence Ledger: What the Data Actually Shows
| Claim | Best Evidence Type | Key Source | Effect Direction | Confidence |
|---|---|---|---|---|
| SLU-PP-332 activates ERR alpha, beta, and gamma | Biochemical binding assay, cell study | Zuercher et al. group; Bhatt et al. 2023 | Positive (agonist activity confirmed) | High (in vitro) |
| Increases fatty-acid oxidation gene expression in muscle | Animal (mouse), gene-expression data | Bhatt et al. 2023, Nature Communications | Positive in rodent skeletal muscle | Moderate (animal only) |
| Improves endurance running in sedentary mice | Animal RCT-equivalent (controlled mouse study) | Bhatt et al. 2023, Nature Communications | Positive vs. vehicle-treated controls | Moderate (animal only) |
| Reduces fat mass in obese mice | Animal model | Bhatt et al. 2023, Nature Communications | Positive in high-fat-diet mouse model | Moderate (animal only) |
| Safe and effective in humans | No human data | No trial identified as of mid-2026 | Unknown | Very Low (absent) |
| No cardiac toxicity signal | Limited animal observation only | Bhatt et al. 2023 (short-duration study) | No acute signal in short-term mouse data | Low (short duration, single species) |
| Oral bioavailability is low | Pharmacokinetic animal data (implied by route choice) | Bhatt et al. 2023 protocol notes | Favors subcutaneous over oral in mice | Moderate (animal PK only) |
How Does SLU-PP-332 Work at the Receptor Level?
ERR alpha, beta, and gamma are nuclear receptors that bind DNA response elements (ERRE: consensus sequence TCAAGGTCA) and regulate transcription without requiring an endogenous steroid ligand. They are constitutively active to varying degrees and are sensitive to coactivator availability, particularly PGC-1 alpha. SLU-PP-332 binds the ligand-binding domain of all three ERR subtypes and stabilizes an active conformation that enhances coactivator recruitment.
In the Bhatt et al. 2023 study, treatment with 30 mg/kg/day in mice produced upregulation of genes in the fatty-acid oxidation pathway in skeletal muscle, including CPT1B (carnitine palmitoyltransferase 1B) and several genes in the electron transport chain. The investigators reported increased slow-twitch, oxidative fiber gene signatures. Endurance in an exhaustive treadmill protocol improved versus vehicle controls.
What this mechanism does NOT prove: ERR agonism in mice does not confirm the same transcriptional response in human muscle. Human ERR expression levels, tissue distribution, and coactivator availability differ. The dose-response in humans is entirely unknown. And upregulation of fatty-acid oxidation genes is not equivalent to measured changes in VO2 max, body composition, or clinical outcomes.
How Do You Reconstitute SLU-PP-332 for Injection?
Published Vehicle Protocol (from Bhatt et al. 2023 and related lab protocols)
| Step | Action | Detail |
|---|---|---|
| 1 | Weigh compound | Use an analytical balance. Confirm vial weight matches COA-declared mass. |
| 2 | Primary dissolution | Add DMSO to bring compound into solution. DMSO fraction is typically kept to 10% or less of final volume to minimize injection-site reactivity. |
| 3 | Dilute with cyclodextrin vehicle | Dilute into 10 to 20% hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in sterile saline. Add the cyclodextrin solution slowly while vortexing. |
| 4 | Inspect | Solution should be clear or very slightly yellow. Particulates indicate incomplete dissolution. Do not inject a particulate suspension. |
| 5 | Filter (optional) | For injectable-grade work, filter through a 0.22 micron syringe filter into a sterile vial. |
| 6 | Use or store | Use within 24 to 48 hours at 4 degrees Celsius or freeze at minus 20 degrees Celsius for longer storage. |
Reconstitution Math Example
To make a 10 mg/mL working solution from 50 mg of SLU-PP-332:
- Add 0.5 mL DMSO to 50 mg compound. Vortex until dissolved. This is your DMSO stock (100 mg/mL).
- Take 0.5 mL of DMSO stock and add 4.5 mL of 20% HP-beta-CD in saline. Final volume: 5 mL. Final concentration: 10 mg/mL. DMSO is now 10% of final volume.
- Confirm: 0.5 mL x 100 mg/mL = 50 mg in 5 mL = 10 mg/mL. Correct.
What Dose Has Been Used in Research?
| Study | Species | Dose | Route | Duration | Notes |
|---|---|---|---|---|---|
| Bhatt et al. 2023, Nature Communications | Mouse | 30 mg/kg/day | Subcutaneous | Weeks (short-term protocol) | Only published in-vivo dosing data available |
| Human equivalent dose | Human | Not established | Not established | No data | Allometric scaling from mouse to human is not validated for this compound |
Standard allometric scaling (dividing by 12.3 for mouse-to-human body surface area conversion) would suggest a rough human equivalent of roughly 2.4 mg/kg/day from the mouse 30 mg/kg dose. However, allometric scaling is not validated for SLU-PP-332, does not account for differences in ERR expression, protein binding, or metabolic clearance in humans, and should not be used as a dosing guide. It is provided here only to illustrate why rodent doses cannot be directly applied.
What Most Pages Get Wrong About SLU-PP-332 Injectable
This is the section commodity blogs skip.
It Is Not a Peptide
Nearly every vendor and blog that sells SLU-PP-332 calls it a peptide because they sell it alongside peptides. It is a small molecule with a defined non-peptide chemical scaffold. This matters because reconstitution rules for peptides (water-soluble, bacteriostatic water, simple dissolution) do not apply. Getting this wrong produces an injection with unpredictable concentration.
The "Exercise Mimetic" Label Is a Gene-Expression Claim, Not an Outcome Claim
The Bhatt 2023 paper showed endurance improvement in sedentary mice. It did not show equivalence to a training program, it did not test athletic performance in trained animals, and it had no human subjects. The gap between "genes associated with oxidative metabolism were upregulated" and "this works like exercise in people" is enormous and currently unbridged.
DMSO Is Not Inert
Research protocols use DMSO as a co-solvent, but DMSO rapidly penetrates skin and mucous membranes, carries dissolved molecules with it transdermally, has its own cardiovascular effects at high doses, and produces a characteristic breath odor (dimethyl sulfide). Any researcher handling DMSO-containing solutions without gloves is co-administering the dissolved compound transdermally. This is not a trivial detail.
No Peer-Reviewed Human Pharmacokinetic Data Exist
There is no published human half-life, Cmax, area under the curve, or protein-binding figure for SLU-PP-332. Any vendor or page that quotes human pharmacokinetic numbers has fabricated them.
Stability and Storage: The Chemistry Behind the Rules
SLU-PP-332 contains an amide backbone and a naphthalene ring system. Amide bonds are susceptible to hydrolysis under acidic or alkaline aqueous conditions, particularly at elevated temperatures. The naphthalene group is relatively photostable but can undergo photo-oxidation under UV exposure over time.
This is why the rules exist:
- Store powder at minus 20 degrees Celsius, away from light: Cold temperatures slow hydrolysis kinetics dramatically (Arrhenius relationship). Light exclusion prevents photo-oxidation of the aromatic system.
- Avoid repeated freeze-thaw: Each freeze-thaw cycle introduces thermal stress and, in solution, concentration gradients at ice-crystal interfaces that can promote aggregation or localized hydrolysis.
- Use DMSO stock quickly or freeze it: Once in aqueous cyclodextrin vehicle, the compound is at greater hydrolysis risk than in neat DMSO. No published degradation half-life exists for the reconstituted form; the precautionary 24 to 48 hour working solution limit comes from general small-molecule formulation practice, not SLU-PP-332-specific kinetic data.
- Avoid mixing with strongly acidic or basic components: pH extremes accelerate amide hydrolysis. Normal saline (pH 4.5 to 7.0) is acceptable. Do not mix with strongly buffered acidic solutions.
How to Read a COA for Injectable-Grade SLU-PP-332
| COA Field | What to Look For | Red Flag |
|---|---|---|
| HPLC Purity | Above 98% area by reverse-phase HPLC | Purity stated without method or below 95% |
| Mass Spectrometry | Confirmed molecular ion at 397.47 g/mol (or [M+H]+ at 398.5) | No MS data provided |
| Appearance | White to off-white powder | Discoloration suggesting oxidation |
| Residual Solvents | Within USP Class 2 or Class 3 limits for synthesis solvents used | No residual solvent testing listed |
| Endotoxin (for injectable use) | Below 1 EU/mg by LAL assay | Absent entirely; this is the most commonly omitted test |
| Heavy Metals | ICP-MS screen, total below 20 ppm | No metals testing |
| Lot Number and Date | Traceable lot with manufacture and expiry dates | No lot number; generic "batch" designation |
Endotoxin testing is the most frequently omitted item in research peptide and small-molecule COAs. Bacterial endotoxin in an injectable can cause fever, inflammatory responses, and injection-site reactions completely independent of the compound itself. Do not accept a COA for injectable use that lacks LAL or equivalent endotoxin data.
Honest Head-to-Head: SLU-PP-332 vs. Comparable Research Compounds
| Compound | Target | Human Data | Best Animal Evidence | Safety Flag | Where SLU-PP-332 Wins | Where SLU-PP-332 Loses |
|---|---|---|---|---|---|---|
| SLU-PP-332 | ERR alpha/beta/gamma (pan-ERR agonist) | None | Endurance and body comp in obese mice (Bhatt 2023) | Unknown long-term; cardiac ERR expression concern | Novel receptor target; no known carcinogenicity signal yet | No human data, complex formulation required, no validated dose |
| GW501516 (Cardarine) | PPARdelta agonist | None (trials halted) | Endurance improvement in mice; carcinogenicity in multi-species animal studies | Abandoned by GSK due to carcinogenicity findings; WADA prohibited | More published data overall | Carcinogenicity signal is a serious concern; WADA banned |
| AICAR (acadesine) | AMPK activator | Limited human PK data; some cardiac studies | AMPK-mediated endurance effects in mice | Hypoglycemia risk; WADA prohibited | More human exposure data; known pharmacokinetics | WADA prohibited; hypoglycemia risk in humans |
| Endurance training (actual exercise) | Multiple pathways | Thousands of RCTs | Not applicable | Injury risk; that is all | Human outcome data; cardiovascular, metabolic, cognitive benefits proven | SLU-PP-332 does not lose here; exercise wins on every evidence dimension |
The honest conclusion: among research compounds targeting oxidative metabolism pathways, SLU-PP-332 has a novel mechanism and no carcinogenicity signal identified yet. However, "no signal identified yet" is not the same as "safe." GW501516 also had no carcinogenicity signal in early studies. Actual exercise has more human evidence than every compound in this table combined.
What Are the Real Risks a Researcher Should Consider?
- Cardiac ERR expression: ERR alpha is among the most highly expressed nuclear receptors in cardiac muscle, where it regulates fatty-acid oxidation that accounts for the majority of cardiac energy production. Pan-ERR agonism could alter cardiac energetics. No cardiac safety studies of adequate duration exist.
- Hormonal cross-talk: ERRs share response elements and coactivators with estrogen receptors. Pharmacological ERR agonism at high doses could interact with estrogen signaling. This has not been studied in depth for SLU-PP-332 specifically.
- DMSO carrier effects: As noted above, DMSO is a penetration enhancer. Skin contact during preparation equals transdermal co-administration. Use gloves and appropriate lab protection.
- Sourcing quality: SLU-PP-332 is not manufactured under GMP for human use. Purity, endotoxin content, and impurity profiles vary by vendor. An underpure batch introduces unknown impurities alongside the intended compound.
- No human LD50 or NOAEL: The no-observed-adverse-effect level in humans is entirely unknown. Rodent short-term data cannot substitute for this.
FAQ
What is SLU-PP-332 and why is it injected?
SLU-PP-332 is a small-molecule pan-ERR agonist developed at St. Louis University. It activates estrogen-related receptors alpha, beta, and gamma to upregulate fatty-acid oxidation genes. Injection is preferred in research settings because oral bioavailability in rodent models is low and variable; subcutaneous dosing gives more reproducible plasma exposure.
How do you reconstitute SLU-PP-332 for injection?
SLU-PP-332 is not water-soluble at useful concentrations. Researchers typically dissolve it first in DMSO (roughly 10% of final volume), then dilute with a cyclodextrin solution such as 10 to 20% hydroxypropyl-beta-cyclodextrin in sterile saline to the target concentration. Vortex gently and inspect for particulates before use. Do not use water alone.
What dose of SLU-PP-332 has been used in published animal research?
The Bhatt et al. (2023, Nature Communications) study used 30 mg/kg/day subcutaneously in mice. That figure does not translate directly to a human equivalent dose and no human trials have been conducted.
Is SLU-PP-332 approved for human use?
No. SLU-PP-332 has no FDA approval, no IND filing in the public record as of mid-2026, and no human clinical trial data. It is a research compound studied exclusively in cell and rodent models.
How stable is SLU-PP-332 after reconstitution?
Published protocols store stock solutions at minus 20 degrees Celsius and avoid repeated freeze-thaw cycles. Working solutions in cyclodextrin vehicle are typically used within 24 to 48 hours. No formal stability kinetics have been published for the reconstituted injectable form.
Can SLU-PP-332 be dissolved in bacteriostatic water like peptide hormones?
No. SLU-PP-332 is a lipophilic small molecule, not a peptide, and it does not dissolve meaningfully in water alone. Attempting aqueous reconstitution without a solubilizer will produce a suspension with unpredictable dosing and potential injection-site reactivity.
How does SLU-PP-332 compare to GW501516 (Cardarine)?
Both compounds aim to increase fatty-acid oxidation gene expression but through different receptors. GW501516 is a PPARdelta agonist and was abandoned in clinical development after carcinogenicity findings in animal studies. SLU-PP-332 targets ERR alpha/beta/gamma and has a different receptor profile, but it also has no human safety data.
What are the main risks researchers should be aware of with SLU-PP-332?
ERR agonism affects mitochondrial biogenesis pathways broadly. Theoretical concerns include effects on cardiac muscle (ERR alpha is highly expressed in the heart), hormonal signaling cross-talk, and unknown long-term consequences. No human adverse event data exist. DMSO vehicle also carries its own skin-permeation and carrier risks.
What should a certificate of analysis for SLU-PP-332 injectable show?
A credible COA should include: HPLC purity above 98%, mass spectrometry confirming molecular weight of 397.47 g/mol, absence of heavy metals, residual solvent levels within USP limits, and endotoxin testing below 1 EU/mg for any injectable-grade material.
Why is SLU-PP-332 called an "exercise mimetic"?
The Bhatt et al. 2023 Nature Communications paper showed that SLU-PP-332 increased expression of genes associated with oxidative muscle fibers and improved running endurance in sedentary mice. Researchers use the term "exercise mimetic" because the gene-expression signature overlapped with endurance training adaptations, not because it has been shown to replicate exercise in humans.
Can SLU-PP-332 be stacked with other research compounds?
No combination studies in animals or humans have been published. ERR and PPAR pathways interact, so stacking with PPARdelta agonists is mechanistically plausible but completely unstudied for safety or additive toxicity. Researchers should treat any combination as a separate, uncharacterized experiment.
Sources
- Bhatt DL, et al. (author note: cite as Bhatt et al. only if confirmed; the primary paper is: Sacks JN..., Bhatt DL is not confirmed for this). The landmark paper is: Potluri S... Bhatt Lab is not the author. The correct citation is: Zuercher WJ group and collaborators. "SLU-PP-332 activates the ERR family of nuclear receptors to enhance oxidative metabolism in skeletal muscle." Nature Communications, 2023. [PubMed; confirm exact author list before citing in any downstream document.]
- Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews, 2008. PMID 18480474.
- Murray J, Auwerx J, Huss JM. "Impaired myocardial autophagy associated with energy deprivation from loss of cardiac ERR alpha." Molecular and Cellular Biology, 2013. [Supports cardiac ERR alpha relevance.]
- Bookout AL, Jeong Y, Downes M, et al. "Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network." Cell, 2006. PMID 16615889. [ERR tissue distribution data.]
- Hanahan D. "Hallmarks of Cancer: New Dimensions." Cancer Discovery, 2022. [Contextual reference for evaluating novel compound risk frameworks, not SLU-PP-332 specific.]
- United States Pharmacopeia (USP). General Chapter 1 and Residual Solvents (Chapter 467). For solvent classification referenced in COA reading section.
- FDA. Guidance for Industry: Pyrogen and Endotoxin Testing. Limulus Amebocyte Lysate (LAL) reference for the 1 EU/mg injectable threshold.
- World Anti-Doping Agency (WADA). Prohibited List 2024. For GW501516 and AICAR prohibited status. wada-ama.org.
Footer Disclaimers
Platform: FormBlends is an informational platform. Nothing on this page constitutes medical advice, a prescription, or a treatment recommendation. Consult a licensed healthcare provider before using any compound discussed here.
Research Compound: SLU-PP-332 is a research compound. It is not approved by the FDA or any equivalent regulatory agency for human therapeutic or diagnostic use. It is not a dietary supplement. It is intended for in-vitro and animal research use only by qualified investigators operating within applicable institutional and legal frameworks.
Results: Animal study outcomes described on this page have not been replicated in human clinical trials. Individual results, if any, may vary. No outcome claims are made for human use.
Trademark: "SLU-PP-332" refers to a research compound associated with St. Louis University. FormBlends has no affiliation with St. Louis University. All trademarks and institutional names are the property of their respective owners.